BACKGROUND There has been no report to use camrelizumab with chemotherapy for advanced bladder cancer patients with positive programmed death-ligand 1(PD-L1)expression and high tumor mutational burden(TMB).More effect...BACKGROUND There has been no report to use camrelizumab with chemotherapy for advanced bladder cancer patients with positive programmed death-ligand 1(PD-L1)expression and high tumor mutational burden(TMB).More effective predictors of bladder cancer immunotherapy have yet to be explored,and the combination of multiple factors may be more predictive than a single factor.CASE SUMMARY We report the case of a 74-year-old male patient with recurrent metastatic bladder cancer,which demonstrated positive PD-L1 expression and high TMB.The immune checkpoint inhibitor camrelizumab was administered to the patient in combination with gemcitabine and cisplatin.The patient achieved a partial response with a progression-free survival of 11 mo.CONCLUSION This is the first report to use camrelizumab with chemotherapy for advanced bladder cancer patients with positive PD-L1 expression and high TMB.展开更多
文摘BACKGROUND There has been no report to use camrelizumab with chemotherapy for advanced bladder cancer patients with positive programmed death-ligand 1(PD-L1)expression and high tumor mutational burden(TMB).More effective predictors of bladder cancer immunotherapy have yet to be explored,and the combination of multiple factors may be more predictive than a single factor.CASE SUMMARY We report the case of a 74-year-old male patient with recurrent metastatic bladder cancer,which demonstrated positive PD-L1 expression and high TMB.The immune checkpoint inhibitor camrelizumab was administered to the patient in combination with gemcitabine and cisplatin.The patient achieved a partial response with a progression-free survival of 11 mo.CONCLUSION This is the first report to use camrelizumab with chemotherapy for advanced bladder cancer patients with positive PD-L1 expression and high TMB.
